Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 4
2019 1
2020 1
2021 1
2022 5
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean chang chin chuan[Author] (34 results)?
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson E, Morley T, MacRaild S, Tiong IS, Morris R, Dun K, Zordan A, Shah J, Banquet S, Halilovic E, Morris E, Herold MJ, Lessene G, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH. Moujalled DM, et al. Among authors: chua cc. Blood. 2023 Feb 9;141(6):634-644. doi: 10.1182/blood.2022016090. Blood. 2023. PMID: 36219880 Free PMC article.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH; Australasian Leukaemia and Lymphoma Group (ALLG). Tiong IS, et al. Among authors: chua cc. Blood Cancer J. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x. Blood Cancer J. 2024. PMID: 38531863 Free PMC article.
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE, Peng H, Luo MX, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME, Wei AH, Roberts AW, Bryant VL, Anderson MA, Lindeman GJ, Huang DCS, Thijssen R, Gray DHD. Teh CE, et al. Among authors: chua cc. Blood Adv. 2023 Jun 27;7(12):2733-2745. doi: 10.1182/bloodadvances.2022008221. Blood Adv. 2023. PMID: 36521105 Free PMC article.
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.
Enjeti AK, Agarwal R, Blombery P, Chee L, Chua CC, Grigg A, Hamad N, Iland H, Lane S, Perkins A, Singhal D, Tate C, Tiong IS, Ross DM. Enjeti AK, et al. Among authors: chua cc. Pathology. 2022 Jun;54(4):389-398. doi: 10.1016/j.pathol.2022.03.002. Epub 2022 Apr 20. Pathology. 2022. PMID: 35461716 Free article. Review.
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, Potter N, Jovanovic J, Runglall M, Chong CC, Bajel A, Ritchie D, Gray K, Yeoh ZH, McBean M, Gilkes A, Thomas I, Johnson S, Russell NH, Wei AH. Loo S, et al. Among authors: chong cc. Blood. 2022 Dec 1;140(22):2407-2411. doi: 10.1182/blood.2022016567. Blood. 2022. PMID: 35960851 Free PMC article. No abstract available.
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Appelbaum JS, et al. Among authors: chua cc. Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263433 No abstract available.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, Reynolds J, Anstee N, Nguyen T, Loo S, Chua CC, Ashby M, Wiltshire KM, Fleming S, Fong CY, Teh TC, Blombery P, Dillon R, Ivey A, Wei AH. Tiong IS, et al. Among authors: chua cc. J Clin Oncol. 2024 Mar 1:JCO2301599. doi: 10.1200/JCO.23.01599. Online ahead of print. J Clin Oncol. 2024. PMID: 38427924
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
Tedjaseputra A, Kuzich JA, Thiagarajah N, Teh TC, McClelland J, Rahman M, Brook R, Chua CC, Ong DM, Tan SY, Filshie R, Fong CY, Fedele P, Bajel A, Shortt J, Wei AH. Tedjaseputra A, et al. Among authors: chua cc. Leuk Lymphoma. 2022 Nov;63(11):2731-2734. doi: 10.1080/10428194.2022.2087065. Epub 2022 Jun 21. Leuk Lymphoma. 2022. PMID: 35727162 No abstract available.
23 results